Compare VLY & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VLY | INAB |
|---|---|---|
| Founded | 1927 | 2016 |
| Country | United States | United States |
| Employees | 3675 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 14.2M |
| IPO Year | N/A | 2020 |
| Metric | VLY | INAB |
|---|---|---|
| Price | $12.92 | $1.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 1 |
| Target Price | ★ $14.17 | $6.00 |
| AVG Volume (30 Days) | ★ 7.0M | 73.5K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.49% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.52 | N/A |
| Revenue Next Year | $8.60 | N/A |
| P/E Ratio | $13.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.64 | $0.12 |
| 52 Week High | $13.87 | $4.20 |
| Indicator | VLY | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 63.31 | 43.78 |
| Support Level | $11.61 | $1.48 |
| Resistance Level | $13.87 | $2.14 |
| Average True Range (ATR) | 0.30 | 0.16 |
| MACD | 0.12 | -0.01 |
| Stochastic Oscillator | 86.09 | 20.59 |
Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.